Aspire Biopharma Holdings (ASBP) Operating Expenses (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Operating Expenses for 6 consecutive years, with $2.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 231.06% year-over-year to $2.6 million in Q2 2026; TTM through Jun 2026 was $7.3 million, a 57.68% decrease from a year earlier, with the FY2025 full-year figure at $19.4 million, up 1498.12% from the prior year.
• Operating Expenses was $2.6 million for Q2 2026 at Aspire Biopharma Holdings, up from $1.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $15.6 million in Q1 2025 and troughed at $96923.0 in Q2 2024.
• A 5-year average of $1.5 million and a median of $324653.5 in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 41493.38% in 2022 and plunged 89.38% in 2026, its largest moves.
• Over 5 years, Operating Expenses stood at $314030.0 in 2022, then grew by 28.21% to $402615.0 in 2023, then soared by 65.85% to $667722.0 in 2024, then jumped by 176.83% to $1.8 million in 2025, then surged by 43.26% to $2.6 million in 2026.
• The last three Operating Expenses figures came in at $2.6 million (Q2 2026), $1.7 million (Q1 2026), and $1.8 million (Q4 2025), per Business Quant data.